Clear Search sequence regions
Bookmark Forward

QuickView for Doxorubicin (compound)


PubChem
Name: Doxorubicin
PubChem Compound ID: 11387649
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Molecular formula: C27H30ClNO11
Molecular weight: 579.98 g/mol
DrugBank
Identification
Name: Doxorubicin
Name (isomeric): DB00997
Drug Type: small molecule
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Synonyms:
Doxorubicine [INN-French]; Doxorubicin HCl; Doxorubicin Hydrochloride; Doxorubicina [INN-Spanish]; Doxorubicinum [INN-Latin]
Brand: Rubex, Adriablastin, Caelyx, DM2, Adriblastin, Adriamycin Semiquinone, Adriamycin RDF, Resmycin, Adriamycin, Doxo, ADM, Adriblastina, RDF Rubex, Adriamycin PFS, Doxil, Myocet
Category: Antineoplastic Agents, Antibiotics, Antibiotics, Antineoplastic
CAS number: 23214-92-8
Pharmacology
Indication: For the treatment of Koposi's sarcome connected to AIDS.
Pharmacology:
Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural s...
show more »
Mechanism of Action:
Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisom...
show more »
Protein binding: 70%
Route of elimination: Plasma clearance is in the range 324 to 809 mL/min/m2 and is predominately by metabolism and biliary excretion.
Half Life: 55 hours
Clearance: 324-809 mL/min/m2 1088 mL/min/m2 [Men] 433 mL/min/m2 [Women] 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]
Toxicity: LD50=21800 ug/kg (rat, subcutaneous)
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Liberal fluid intake to increase urine output and help the excretion of uric acid.
Drug interaction:
TerbinafineTerbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed.
Dabigatran etexilateP-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
TelithromycinTelithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed.
TrastuzumabTrastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
VoriconazoleVoriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of doxorubicin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxorubicin if voriconazole is initiated, discontinued or dose changed.
show more »

Targets


Enzymes


Transporters